EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Trial Profile

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms EVEREST
  • Most Recent Events

    • 02 Jun 2017 EVE analysis is ongoing and the final results will be presented as per result presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Preliminary results (n=386) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top